nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—CHEK2—peripheral nervous system neoplasm	0.167	0.347	CbGaD
Sunitinib—ALK—peripheral nervous system neoplasm	0.149	0.31	CbGaD
Sunitinib—NTRK1—peripheral nervous system neoplasm	0.145	0.301	CbGaD
Sunitinib—ABCB1—peripheral nervous system neoplasm	0.0203	0.0422	CbGaD
Sunitinib—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0172	0.101	CbGbCtD
Sunitinib—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0119	0.0697	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Tretinoin—peripheral nervous system neoplasm	0.0118	0.069	CbGbCtD
Sunitinib—CYP3A7—Tretinoin—peripheral nervous system neoplasm	0.0118	0.069	CbGbCtD
Sunitinib—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.00885	0.0518	CbGbCtD
Sunitinib—ABCC2—Vincristine—peripheral nervous system neoplasm	0.00811	0.0475	CbGbCtD
Sunitinib—ABCC2—Cisplatin—peripheral nervous system neoplasm	0.00757	0.0443	CbGbCtD
Sunitinib—ABCC2—Etoposide—peripheral nervous system neoplasm	0.00743	0.0435	CbGbCtD
Sunitinib—ABCG2—Vincristine—peripheral nervous system neoplasm	0.00733	0.0429	CbGbCtD
Sunitinib—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.00684	0.04	CbGbCtD
Sunitinib—ABCG2—Etoposide—peripheral nervous system neoplasm	0.00672	0.0393	CbGbCtD
Sunitinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.00619	0.0363	CbGbCtD
Sunitinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.00619	0.0363	CbGbCtD
Sunitinib—CYP3A7-CYP3A51P—Vincristine—peripheral nervous system neoplasm	0.00542	0.0317	CbGbCtD
Sunitinib—CYP3A7—Vincristine—peripheral nervous system neoplasm	0.00542	0.0317	CbGbCtD
Sunitinib—ABCC2—Doxorubicin—peripheral nervous system neoplasm	0.00507	0.0297	CbGbCtD
Sunitinib—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.00458	0.0268	CbGbCtD
Sunitinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.00429	0.0251	CbGbCtD
Sunitinib—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.00406	0.0238	CbGbCtD
Sunitinib—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.00372	0.0218	CbGbCtD
Sunitinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.00371	0.0217	CbGbCtD
Sunitinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00345	0.0202	CbGbCtD
Sunitinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.00264	0.0155	CbGbCtD
Sunitinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00247	0.0144	CbGbCtD
Sunitinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.00242	0.0142	CbGbCtD
Sunitinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00165	0.00967	CbGbCtD
Sunitinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00158	0.00927	CbGbCtD
Sunitinib—MYLK3—tongue—peripheral nervous system neoplasm	0.00155	0.0234	CbGeAlD
Sunitinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00145	0.0085	CbGbCtD
Sunitinib—NIM1K—ganglion—peripheral nervous system neoplasm	0.00137	0.0208	CbGeAlD
Sunitinib—RPS6KA5—ganglion—peripheral nervous system neoplasm	0.00112	0.0169	CbGeAlD
Sunitinib—DAPK1—ganglion—peripheral nervous system neoplasm	0.00104	0.0157	CbGeAlD
Sunitinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00099	0.0058	CbGbCtD
Sunitinib—RPS6KB1—forelimb—peripheral nervous system neoplasm	0.00098	0.0148	CbGeAlD
Sunitinib—FGFR2—skull—peripheral nervous system neoplasm	0.000961	0.0145	CbGeAlD
Sunitinib—ROCK1—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000702	0.216	CbGdCrCtD
Sunitinib—MERTK—ganglion—peripheral nervous system neoplasm	0.000679	0.0103	CbGeAlD
Sunitinib—NIM1K—trigeminal ganglion—peripheral nervous system neoplasm	0.000675	0.0102	CbGeAlD
Sunitinib—NTRK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000647	0.00978	CbGeAlD
Sunitinib—CLK1—ganglion—peripheral nervous system neoplasm	0.000631	0.00954	CbGeAlD
Sunitinib—CAMK2G—nerve—peripheral nervous system neoplasm	0.000627	0.00948	CbGeAlD
Sunitinib—MAP4K4—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000626	0.193	CbGdCrCtD
Sunitinib—LRRK2—nerve—peripheral nervous system neoplasm	0.000621	0.00939	CbGeAlD
Sunitinib—CAMK2G—ganglion—peripheral nervous system neoplasm	0.000619	0.00936	CbGeAlD
Sunitinib—LRRK2—ganglion—peripheral nervous system neoplasm	0.000614	0.00928	CbGeAlD
Sunitinib—DCLK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000601	0.00909	CbGeAlD
Sunitinib—ULK3—ganglion—peripheral nervous system neoplasm	0.000566	0.00856	CbGeAlD
Sunitinib—CDK14—trigeminal ganglion—peripheral nervous system neoplasm	0.000565	0.00855	CbGeAlD
Sunitinib—ULK3—tongue—peripheral nervous system neoplasm	0.00056	0.00847	CbGeAlD
Sunitinib—PAK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000558	0.00843	CbGeAlD
Sunitinib—TLK2—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000532	0.164	CbGdCrCtD
Sunitinib—PAK3—parotid gland—peripheral nervous system neoplasm	0.000526	0.00795	CbGeAlD
Sunitinib—SBK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000523	0.00791	CbGeAlD
Sunitinib—STK11—trigeminal ganglion—peripheral nervous system neoplasm	0.000495	0.00749	CbGeAlD
Sunitinib—CDK16—brainstem—peripheral nervous system neoplasm	0.000493	0.00746	CbGeAlD
Sunitinib—RPS6KA1—trigeminal ganglion—peripheral nervous system neoplasm	0.00049	0.00741	CbGeAlD
Sunitinib—RIOK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00049	0.00741	CbGeAlD
Sunitinib—SGK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000476	0.0072	CbGeAlD
Sunitinib—ICK—trigeminal ganglion—peripheral nervous system neoplasm	0.000472	0.00713	CbGeAlD
Sunitinib—RPS6KA1—parotid gland—peripheral nervous system neoplasm	0.000462	0.00699	CbGeAlD
Sunitinib—RIOK1—parotid gland—peripheral nervous system neoplasm	0.000462	0.00699	CbGeAlD
Sunitinib—NUAK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000456	0.00689	CbGeAlD
Sunitinib—DAPK1—brainstem—peripheral nervous system neoplasm	0.000453	0.00684	CbGeAlD
Sunitinib—OXSR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000452	0.00683	CbGeAlD
Sunitinib—SNRK—trigeminal ganglion—peripheral nervous system neoplasm	0.000452	0.00683	CbGeAlD
Sunitinib—INSR—trigeminal ganglion—peripheral nervous system neoplasm	0.000452	0.00683	CbGeAlD
Sunitinib—SGK3—parotid gland—peripheral nervous system neoplasm	0.000449	0.00679	CbGeAlD
Sunitinib—ICK—parotid gland—peripheral nervous system neoplasm	0.000445	0.00673	CbGeAlD
Sunitinib—RPS6KA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000445	0.00673	CbGeAlD
Sunitinib—STK38—trigeminal ganglion—peripheral nervous system neoplasm	0.000445	0.00673	CbGeAlD
Sunitinib—PKN1—trigeminal ganglion—peripheral nervous system neoplasm	0.000438	0.00662	CbGeAlD
Sunitinib—CSNK1G2—trigeminal ganglion—peripheral nervous system neoplasm	0.000438	0.00662	CbGeAlD
Sunitinib—PRPF4—trigeminal ganglion—peripheral nervous system neoplasm	0.000432	0.00653	CbGeAlD
Sunitinib—NUAK1—parotid gland—peripheral nervous system neoplasm	0.00043	0.0065	CbGeAlD
Sunitinib—OXSR1—parotid gland—peripheral nervous system neoplasm	0.000426	0.00645	CbGeAlD
Sunitinib—Procainamide—BCHE—peripheral nervous system neoplasm	0.000426	1	CrCbGaD
Sunitinib—PRPF4B—trigeminal ganglion—peripheral nervous system neoplasm	0.000426	0.00643	CbGeAlD
Sunitinib—STK39—trigeminal ganglion—peripheral nervous system neoplasm	0.00042	0.00634	CbGeAlD
Sunitinib—CSNK2A1—trigeminal ganglion—peripheral nervous system neoplasm	0.000414	0.00626	CbGeAlD
Sunitinib—HUNK—cerebellum—peripheral nervous system neoplasm	0.000407	0.00616	CbGeAlD
Sunitinib—PRPF4B—parotid gland—peripheral nervous system neoplasm	0.000401	0.00607	CbGeAlD
Sunitinib—STK39—parotid gland—peripheral nervous system neoplasm	0.000396	0.00598	CbGeAlD
Sunitinib—CSNK2A1—parotid gland—peripheral nervous system neoplasm	0.000391	0.0059	CbGeAlD
Sunitinib—DAPK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000388	0.00586	CbGeAlD
Sunitinib—TNK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000375	0.00567	CbGeAlD
Sunitinib—RIOK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000375	0.00567	CbGeAlD
Sunitinib—GRK4—cerebellum—peripheral nervous system neoplasm	0.000372	0.00563	CbGeAlD
Sunitinib—DAPK2—parotid gland—peripheral nervous system neoplasm	0.000366	0.00553	CbGeAlD
Sunitinib—DAPK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000364	0.00551	CbGeAlD
Sunitinib—CLK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000361	0.00546	CbGeAlD
Sunitinib—MAP4K2—trigeminal ganglion—peripheral nervous system neoplasm	0.000359	0.00543	CbGeAlD
Sunitinib—RIOK2—parotid gland—peripheral nervous system neoplasm	0.000354	0.00535	CbGeAlD
Sunitinib—PHKG2—brainstem—peripheral nervous system neoplasm	0.000349	0.00527	CbGeAlD
Sunitinib—MYLK4—cerebellum—peripheral nervous system neoplasm	0.000346	0.00523	CbGeAlD
Sunitinib—CLK2—parotid gland—peripheral nervous system neoplasm	0.00034	0.00515	CbGeAlD
Sunitinib—HIPK2—brainstem—peripheral nervous system neoplasm	0.000336	0.00507	CbGeAlD
Sunitinib—TYRO3—brainstem—peripheral nervous system neoplasm	0.000336	0.00507	CbGeAlD
Sunitinib—MAP4K4—trigeminal ganglion—peripheral nervous system neoplasm	0.000327	0.00495	CbGeAlD
Sunitinib—NUAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000325	0.00491	CbGeAlD
Sunitinib—MAP3K12—trigeminal ganglion—peripheral nervous system neoplasm	0.000322	0.00488	CbGeAlD
Sunitinib—RPS6KA3—trigeminal ganglion—peripheral nervous system neoplasm	0.000318	0.00481	CbGeAlD
Sunitinib—CSNK1A1—trigeminal ganglion—peripheral nervous system neoplasm	0.000312	0.00471	CbGeAlD
Sunitinib—CLK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00031	0.00468	CbGeAlD
Sunitinib—NUAK2—parotid gland—peripheral nervous system neoplasm	0.000306	0.00463	CbGeAlD
Sunitinib—BMP2K—trigeminal ganglion—peripheral nervous system neoplasm	0.000304	0.0046	CbGeAlD
Sunitinib—DYRK1A—brainstem—peripheral nervous system neoplasm	0.000302	0.00456	CbGeAlD
Sunitinib—LRRK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000301	0.00456	CbGeAlD
Sunitinib—RPS6KA3—parotid gland—peripheral nervous system neoplasm	0.0003	0.00454	CbGeAlD
Sunitinib—NIM1K—cerebellum—peripheral nervous system neoplasm	0.000294	0.00445	CbGeAlD
Sunitinib—CSNK1A1—parotid gland—peripheral nervous system neoplasm	0.000294	0.00445	CbGeAlD
Sunitinib—CLK1—parotid gland—peripheral nervous system neoplasm	0.000292	0.00442	CbGeAlD
Sunitinib—CSNK1E—trigeminal ganglion—peripheral nervous system neoplasm	0.000289	0.00437	CbGeAlD
Sunitinib—FGFR1—trigeminal ganglion—peripheral nervous system neoplasm	0.000289	0.00437	CbGeAlD
Sunitinib—MAP3K12—brainstem—peripheral nervous system neoplasm	0.000285	0.00431	CbGeAlD
Sunitinib—IRAK4—trigeminal ganglion—peripheral nervous system neoplasm	0.000284	0.0043	CbGeAlD
Sunitinib—PRKAA2—cerebellum—peripheral nervous system neoplasm	0.000282	0.00427	CbGeAlD
Sunitinib—MAP2K1—brainstem—peripheral nervous system neoplasm	0.00028	0.00423	CbGeAlD
Sunitinib—ULK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000278	0.0042	CbGeAlD
Sunitinib—MAP2K2—trigeminal ganglion—peripheral nervous system neoplasm	0.000278	0.0042	CbGeAlD
Sunitinib—MAST1—cerebellum—peripheral nervous system neoplasm	0.000277	0.00418	CbGeAlD
Sunitinib—MAP3K7—trigeminal ganglion—peripheral nervous system neoplasm	0.000274	0.00414	CbGeAlD
Sunitinib—CSNK1E—parotid gland—peripheral nervous system neoplasm	0.000273	0.00412	CbGeAlD
Sunitinib—STK17B—cerebellum—peripheral nervous system neoplasm	0.000272	0.00411	CbGeAlD
Sunitinib—TBK1—trigeminal ganglion—peripheral nervous system neoplasm	0.00027	0.00409	CbGeAlD
Sunitinib—CAMK2G—brainstem—peripheral nervous system neoplasm	0.000269	0.00407	CbGeAlD
Sunitinib—TYK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000269	0.00406	CbGeAlD
Sunitinib—IRAK4—parotid gland—peripheral nervous system neoplasm	0.000268	0.00406	CbGeAlD
Sunitinib—LRRK2—brainstem—peripheral nervous system neoplasm	0.000267	0.00403	CbGeAlD
Sunitinib—ULK3—parotid gland—peripheral nervous system neoplasm	0.000262	0.00397	CbGeAlD
Sunitinib—RPS6KB1—trigeminal ganglion—peripheral nervous system neoplasm	0.00026	0.00393	CbGeAlD
Sunitinib—RET—trigeminal ganglion—peripheral nervous system neoplasm	0.000259	0.00391	CbGeAlD
Sunitinib—MAP3K7—parotid gland—peripheral nervous system neoplasm	0.000258	0.0039	CbGeAlD
Sunitinib—AXL—trigeminal ganglion—peripheral nervous system neoplasm	0.000258	0.00389	CbGeAlD
Sunitinib—TBK1—parotid gland—peripheral nervous system neoplasm	0.000255	0.00386	CbGeAlD
Sunitinib—TYK2—parotid gland—peripheral nervous system neoplasm	0.000253	0.00383	CbGeAlD
Sunitinib—STK17A—cerebellum—peripheral nervous system neoplasm	0.00025	0.00378	CbGeAlD
Sunitinib—SLK—trigeminal ganglion—peripheral nervous system neoplasm	0.000248	0.00375	CbGeAlD
Sunitinib—CDK14—cerebellum—peripheral nervous system neoplasm	0.000247	0.00373	CbGeAlD
Sunitinib—RPS6KB1—parotid gland—peripheral nervous system neoplasm	0.000245	0.00371	CbGeAlD
Sunitinib—JAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000244	0.00369	CbGeAlD
Sunitinib—PAK3—cerebellum—peripheral nervous system neoplasm	0.000243	0.00368	CbGeAlD
Sunitinib—CDK16—cerebellum—peripheral nervous system neoplasm	0.000243	0.00368	CbGeAlD
Sunitinib—LATS2—cerebellum—peripheral nervous system neoplasm	0.000243	0.00368	CbGeAlD
Sunitinib—FYN—trigeminal ganglion—peripheral nervous system neoplasm	0.000241	0.00364	CbGeAlD
Sunitinib—STK33—cerebellum—peripheral nervous system neoplasm	0.00024	0.00363	CbGeAlD
Sunitinib—RPS6KA5—cerebellum—peripheral nervous system neoplasm	0.00024	0.00363	CbGeAlD
Sunitinib—MAP3K3—trigeminal ganglion—peripheral nervous system neoplasm	0.000236	0.00356	CbGeAlD
Sunitinib—MAP4K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000236	0.00356	CbGeAlD
Sunitinib—STK24—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000234	0.0721	CbGdCrCtD
Sunitinib—SLK—parotid gland—peripheral nervous system neoplasm	0.000234	0.00353	CbGeAlD
Sunitinib—CLK4—cerebellum—peripheral nervous system neoplasm	0.000231	0.00349	CbGeAlD
Sunitinib—SBK1—cerebellum—peripheral nervous system neoplasm	0.000228	0.00345	CbGeAlD
Sunitinib—FLT1—trigeminal ganglion—peripheral nervous system neoplasm	0.000228	0.00344	CbGeAlD
Sunitinib—EPHB6—trigeminal ganglion—peripheral nervous system neoplasm	0.000225	0.0034	CbGeAlD
Sunitinib—DAPK1—cerebellum—peripheral nervous system neoplasm	0.000223	0.00337	CbGeAlD
Sunitinib—PHKG1—cerebellum—peripheral nervous system neoplasm	0.000223	0.00337	CbGeAlD
Sunitinib—MAP4K5—parotid gland—peripheral nervous system neoplasm	0.000222	0.00336	CbGeAlD
Sunitinib—MAP3K3—parotid gland—peripheral nervous system neoplasm	0.000222	0.00336	CbGeAlD
Sunitinib—YES1—trigeminal ganglion—peripheral nervous system neoplasm	0.000218	0.00329	CbGeAlD
Sunitinib—FGFR2—brainstem—peripheral nervous system neoplasm	0.000217	0.00329	CbGeAlD
Sunitinib—STK11—cerebellum—peripheral nervous system neoplasm	0.000216	0.00327	CbGeAlD
Sunitinib—BRD4—cerebellum—peripheral nervous system neoplasm	0.000216	0.00327	CbGeAlD
Sunitinib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000216	0.00326	CbGeAlD
Sunitinib—FLT1—parotid gland—peripheral nervous system neoplasm	0.000215	0.00325	CbGeAlD
Sunitinib—TAOK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000215	0.00325	CbGeAlD
Sunitinib—RPS6KA1—cerebellum—peripheral nervous system neoplasm	0.000214	0.00323	CbGeAlD
Sunitinib—RIOK1—cerebellum—peripheral nervous system neoplasm	0.000214	0.00323	CbGeAlD
Sunitinib—FYN—brainstem—peripheral nervous system neoplasm	0.000213	0.00322	CbGeAlD
Sunitinib—EPHB6—parotid gland—peripheral nervous system neoplasm	0.000212	0.00321	CbGeAlD
Sunitinib—TNIK—cerebellum—peripheral nervous system neoplasm	0.00021	0.00317	CbGeAlD
Sunitinib—MARK2—cerebellum—peripheral nervous system neoplasm	0.00021	0.00317	CbGeAlD
Sunitinib—SGK3—cerebellum—peripheral nervous system neoplasm	0.000208	0.00314	CbGeAlD
Sunitinib—ICK—cerebellum—peripheral nervous system neoplasm	0.000206	0.00311	CbGeAlD
Sunitinib—YES1—parotid gland—peripheral nervous system neoplasm	0.000205	0.0031	CbGeAlD
Sunitinib—TAOK3—parotid gland—peripheral nervous system neoplasm	0.000203	0.00306	CbGeAlD
Sunitinib—NUAK1—cerebellum—peripheral nervous system neoplasm	0.000199	0.00301	CbGeAlD
Sunitinib—INSR—cerebellum—peripheral nervous system neoplasm	0.000197	0.00298	CbGeAlD
Sunitinib—OXSR1—cerebellum—peripheral nervous system neoplasm	0.000197	0.00298	CbGeAlD
Sunitinib—SNRK—cerebellum—peripheral nervous system neoplasm	0.000197	0.00298	CbGeAlD
Sunitinib—STK38—cerebellum—peripheral nervous system neoplasm	0.000194	0.00293	CbGeAlD
Sunitinib—RPS6KA2—cerebellum—peripheral nervous system neoplasm	0.000194	0.00293	CbGeAlD
Sunitinib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000193	0.00291	CbGeAlD
Sunitinib—KDR—trigeminal ganglion—peripheral nervous system neoplasm	0.000193	0.00291	CbGeAlD
Sunitinib—CSNK1G2—cerebellum—peripheral nervous system neoplasm	0.000191	0.00289	CbGeAlD
Sunitinib—PKN1—cerebellum—peripheral nervous system neoplasm	0.000191	0.00289	CbGeAlD
Sunitinib—TAOK3—brainstem—peripheral nervous system neoplasm	0.00019	0.00287	CbGeAlD
Sunitinib—PRPF4—cerebellum—peripheral nervous system neoplasm	0.000188	0.00285	CbGeAlD
Sunitinib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000188	0.00284	CbGeAlD
Sunitinib—PRPF4B—cerebellum—peripheral nervous system neoplasm	0.000186	0.00281	CbGeAlD
Sunitinib—STK39—cerebellum—peripheral nervous system neoplasm	0.000183	0.00277	CbGeAlD
Sunitinib—KDR—parotid gland—peripheral nervous system neoplasm	0.000182	0.00274	CbGeAlD
Sunitinib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000182	0.00274	CbGeAlD
Sunitinib—CSNK2A1—cerebellum—peripheral nervous system neoplasm	0.000181	0.00273	CbGeAlD
Sunitinib—MYLK—cerebellum—peripheral nervous system neoplasm	0.000178	0.0027	CbGeAlD
Sunitinib—STK4—cerebellum—peripheral nervous system neoplasm	0.000175	0.00265	CbGeAlD
Sunitinib—PHKG2—cerebellum—peripheral nervous system neoplasm	0.000172	0.0026	CbGeAlD
Sunitinib—STK24—cerebellum—peripheral nervous system neoplasm	0.000171	0.00259	CbGeAlD
Sunitinib—KIT—trigeminal ganglion—peripheral nervous system neoplasm	0.000171	0.00258	CbGeAlD
Sunitinib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.00017	0.00258	CbGeAlD
Sunitinib—DAPK2—cerebellum—peripheral nervous system neoplasm	0.000169	0.00256	CbGeAlD
Sunitinib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000167	0.00252	CbGeAlD
Sunitinib—STK16—cerebellum—peripheral nervous system neoplasm	0.000166	0.00251	CbGeAlD
Sunitinib—HIPK2—cerebellum—peripheral nervous system neoplasm	0.000165	0.0025	CbGeAlD
Sunitinib—HIPK3—cerebellum—peripheral nervous system neoplasm	0.000165	0.0025	CbGeAlD
Sunitinib—TYRO3—cerebellum—peripheral nervous system neoplasm	0.000165	0.0025	CbGeAlD
Sunitinib—TNK1—cerebellum—peripheral nervous system neoplasm	0.000164	0.00248	CbGeAlD
Sunitinib—RIOK2—cerebellum—peripheral nervous system neoplasm	0.000164	0.00248	CbGeAlD
Sunitinib—KIT—parotid gland—peripheral nervous system neoplasm	0.000161	0.00243	CbGeAlD
Sunitinib—DAPK3—cerebellum—peripheral nervous system neoplasm	0.000159	0.0024	CbGeAlD
Sunitinib—CLK2—cerebellum—peripheral nervous system neoplasm	0.000157	0.00238	CbGeAlD
Sunitinib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000157	0.00238	CbGeAlD
Sunitinib—MAP4K2—cerebellum—peripheral nervous system neoplasm	0.000157	0.00237	CbGeAlD
Sunitinib—STK3—cerebellum—peripheral nervous system neoplasm	0.000155	0.00234	CbGeAlD
Sunitinib—KIT—brainstem—peripheral nervous system neoplasm	0.000151	0.00228	CbGeAlD
Sunitinib—DYRK1A—cerebellum—peripheral nervous system neoplasm	0.000149	0.00225	CbGeAlD
Sunitinib—MERTK—cerebellum—peripheral nervous system neoplasm	0.000145	0.0022	CbGeAlD
Sunitinib—MAP4K4—cerebellum—peripheral nervous system neoplasm	0.000143	0.00216	CbGeAlD
Sunitinib—NUAK2—cerebellum—peripheral nervous system neoplasm	0.000142	0.00214	CbGeAlD
Sunitinib—MAP3K12—cerebellum—peripheral nervous system neoplasm	0.000141	0.00213	CbGeAlD
Sunitinib—FLT3—cerebellum—peripheral nervous system neoplasm	0.000141	0.00213	CbGeAlD
Sunitinib—RPS6KA3—cerebellum—peripheral nervous system neoplasm	0.000139	0.0021	CbGeAlD
Sunitinib—MAP2K1—cerebellum—peripheral nervous system neoplasm	0.000138	0.00208	CbGeAlD
Sunitinib—CSNK1A1—cerebellum—peripheral nervous system neoplasm	0.000136	0.00206	CbGeAlD
Sunitinib—CLK1—cerebellum—peripheral nervous system neoplasm	0.000135	0.00204	CbGeAlD
Sunitinib—CAMK2G—cerebellum—peripheral nervous system neoplasm	0.000133	0.00201	CbGeAlD
Sunitinib—BMP2K—cerebellum—peripheral nervous system neoplasm	0.000133	0.00201	CbGeAlD
Sunitinib—LRRK2—cerebellum—peripheral nervous system neoplasm	0.000132	0.00199	CbGeAlD
Sunitinib—PRKAA1—cerebellum—peripheral nervous system neoplasm	0.00013	0.00196	CbGeAlD
Sunitinib—PTK2B—cerebellum—peripheral nervous system neoplasm	0.000128	0.00194	CbGeAlD
Sunitinib—CSNK1E—cerebellum—peripheral nervous system neoplasm	0.000126	0.00191	CbGeAlD
Sunitinib—FGFR1—cerebellum—peripheral nervous system neoplasm	0.000126	0.00191	CbGeAlD
Sunitinib—IRAK4—cerebellum—peripheral nervous system neoplasm	0.000124	0.00188	CbGeAlD
Sunitinib—ULK3—cerebellum—peripheral nervous system neoplasm	0.000121	0.00183	CbGeAlD
Sunitinib—MAP2K2—cerebellum—peripheral nervous system neoplasm	0.000121	0.00183	CbGeAlD
Sunitinib—MAP3K2—cerebellum—peripheral nervous system neoplasm	0.00012	0.00182	CbGeAlD
Sunitinib—MAP3K7—cerebellum—peripheral nervous system neoplasm	0.000119	0.0018	CbGeAlD
Sunitinib—TBK1—cerebellum—peripheral nervous system neoplasm	0.000118	0.00178	CbGeAlD
Sunitinib—TYK2—cerebellum—peripheral nervous system neoplasm	0.000117	0.00177	CbGeAlD
Sunitinib—IRAK1—cerebellum—peripheral nervous system neoplasm	0.000116	0.00175	CbGeAlD
Sunitinib—RPS6KB1—cerebellum—peripheral nervous system neoplasm	0.000114	0.00172	CbGeAlD
Sunitinib—RET—cerebellum—peripheral nervous system neoplasm	0.000113	0.00171	CbGeAlD
Sunitinib—AXL—cerebellum—peripheral nervous system neoplasm	0.000112	0.0017	CbGeAlD
Sunitinib—SLK—cerebellum—peripheral nervous system neoplasm	0.000108	0.00164	CbGeAlD
Sunitinib—FGFR2—cerebellum—peripheral nervous system neoplasm	0.000107	0.00162	CbGeAlD
Sunitinib—JAK2—cerebellum—peripheral nervous system neoplasm	0.000107	0.00161	CbGeAlD
Sunitinib—KCNH2—trigeminal ganglion—peripheral nervous system neoplasm	0.000105	0.00159	CbGeAlD
Sunitinib—FYN—cerebellum—peripheral nervous system neoplasm	0.000105	0.00159	CbGeAlD
Sunitinib—CHEK2—Vindesine—Vincristine—peripheral nervous system neoplasm	0.000104	0.0321	CbGdCrCtD
Sunitinib—MAP3K3—cerebellum—peripheral nervous system neoplasm	0.000103	0.00155	CbGeAlD
Sunitinib—MAP4K5—cerebellum—peripheral nervous system neoplasm	0.000103	0.00155	CbGeAlD
Sunitinib—FLT1—cerebellum—peripheral nervous system neoplasm	9.94e-05	0.0015	CbGeAlD
Sunitinib—EPHB6—cerebellum—peripheral nervous system neoplasm	9.82e-05	0.00148	CbGeAlD
Sunitinib—YES1—cerebellum—peripheral nervous system neoplasm	9.49e-05	0.00143	CbGeAlD
Sunitinib—STK10—cerebellum—peripheral nervous system neoplasm	9.41e-05	0.00142	CbGeAlD
Sunitinib—TAOK3—cerebellum—peripheral nervous system neoplasm	9.37e-05	0.00142	CbGeAlD
Sunitinib—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	9.37e-05	0.00142	CbGeAlD
Sunitinib—PDGFRA—cerebellum—peripheral nervous system neoplasm	9.31e-05	0.00141	CbGeAlD
Sunitinib—ABCG2—parotid gland—peripheral nervous system neoplasm	8.83e-05	0.00134	CbGeAlD
Sunitinib—KDR—cerebellum—peripheral nervous system neoplasm	8.4e-05	0.00127	CbGeAlD
Sunitinib—MAP2K5—cerebellum—peripheral nervous system neoplasm	8.4e-05	0.00127	CbGeAlD
Sunitinib—CSF1R—cerebellum—peripheral nervous system neoplasm	8.2e-05	0.00124	CbGeAlD
Sunitinib—PLK4—Teniposide—Etoposide—peripheral nervous system neoplasm	7.46e-05	0.0229	CbGdCrCtD
Sunitinib—KIT—cerebellum—peripheral nervous system neoplasm	7.44e-05	0.00113	CbGeAlD
Sunitinib—PDGFRB—cerebellum—peripheral nervous system neoplasm	7.27e-05	0.0011	CbGeAlD
Sunitinib—CHEK2—Vinorelbine—Vincristine—peripheral nervous system neoplasm	6.58e-05	0.0202	CbGdCrCtD
Sunitinib—CHEK2—Teniposide—Etoposide—peripheral nervous system neoplasm	6.58e-05	0.0202	CbGdCrCtD
Sunitinib—CHEK2—Podofilox—Etoposide—peripheral nervous system neoplasm	6.58e-05	0.0202	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Epirubicin—peripheral nervous system neoplasm	5.7e-05	0.0175	CbGdCrCtD
Sunitinib—DYRK1A—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	5.7e-05	0.0175	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	5.7e-05	0.0175	CbGdCrCtD
Sunitinib—DYRK1A—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	5.27e-05	0.0162	CbGdCrCtD
Sunitinib—DYRK1A—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	5.27e-05	0.0162	CbGdCrCtD
Sunitinib—DYRK1A—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	5.27e-05	0.0162	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	4.92e-05	0.0151	CbGdCrCtD
Sunitinib—PRPF4—Idarubicin—Epirubicin—peripheral nervous system neoplasm	4.92e-05	0.0151	CbGdCrCtD
Sunitinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	4.62e-05	0.000698	CbGeAlD
Sunitinib—KCNH2—cerebellum—peripheral nervous system neoplasm	4.59e-05	0.000694	CbGeAlD
Sunitinib—PRPF4—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.014	CbGdCrCtD
Sunitinib—PRPF4—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	4.55e-05	0.014	CbGdCrCtD
Sunitinib—CHEK2—Vinblastine—Vincristine—peripheral nervous system neoplasm	4.53e-05	0.0139	CbGdCrCtD
Sunitinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000293	CcSEcCtD
Sunitinib—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000293	CcSEcCtD
Sunitinib—Nausea—Tretinoin—peripheral nervous system neoplasm	4.11e-05	0.000293	CcSEcCtD
Sunitinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	4.11e-05	0.000293	CcSEcCtD
Sunitinib—ABCG2—cerebellum—peripheral nervous system neoplasm	4.09e-05	0.000618	CbGeAlD
Sunitinib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	4.07e-05	0.00029	CcSEcCtD
Sunitinib—Infection—Etoposide—peripheral nervous system neoplasm	4.07e-05	0.00029	CcSEcCtD
Sunitinib—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	4.06e-05	0.000289	CcSEcCtD
Sunitinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	4.06e-05	0.000289	CcSEcCtD
Sunitinib—Nausea—Melphalan—peripheral nervous system neoplasm	4.06e-05	0.000289	CcSEcCtD
Sunitinib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	4.05e-05	0.000288	CcSEcCtD
Sunitinib—Dysphagia—Epirubicin—peripheral nervous system neoplasm	4.03e-05	0.000287	CcSEcCtD
Sunitinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	4.02e-05	0.000286	CcSEcCtD
Sunitinib—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	4.01e-05	0.000286	CcSEcCtD
Sunitinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	4.01e-05	0.000286	CcSEcCtD
Sunitinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	3.99e-05	0.000285	CcSEcCtD
Sunitinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	3.99e-05	0.000285	CcSEcCtD
Sunitinib—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000284	CcSEcCtD
Sunitinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	3.98e-05	0.000284	CcSEcCtD
Sunitinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	3.97e-05	0.000283	CcSEcCtD
Sunitinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000282	CcSEcCtD
Sunitinib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	3.95e-05	0.000282	CcSEcCtD
Sunitinib—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	3.94e-05	0.000281	CcSEcCtD
Sunitinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.00028	CcSEcCtD
Sunitinib—Anorexia—Etoposide—peripheral nervous system neoplasm	3.9e-05	0.000278	CcSEcCtD
Sunitinib—PLK4—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.012	CbGdCrCtD
Sunitinib—PLK4—Idarubicin—Epirubicin—peripheral nervous system neoplasm	3.89e-05	0.012	CbGdCrCtD
Sunitinib—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	3.89e-05	0.000277	CcSEcCtD
Sunitinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	3.89e-05	0.000277	CcSEcCtD
Sunitinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	3.88e-05	0.000277	CcSEcCtD
Sunitinib—Bronchitis—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000276	CcSEcCtD
Sunitinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	3.87e-05	0.000276	CcSEcCtD
Sunitinib—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	3.86e-05	0.000275	CcSEcCtD
Sunitinib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000275	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	3.86e-05	0.000275	CcSEcCtD
Sunitinib—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	3.83e-05	0.000273	CcSEcCtD
Sunitinib—Pain—Cisplatin—peripheral nervous system neoplasm	3.82e-05	0.000272	CcSEcCtD
Sunitinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000271	CcSEcCtD
Sunitinib—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	3.81e-05	0.000271	CcSEcCtD
Sunitinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000269	CcSEcCtD
Sunitinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	3.76e-05	0.000268	CcSEcCtD
Sunitinib—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000268	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000267	CcSEcCtD
Sunitinib—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	3.73e-05	0.000266	CcSEcCtD
Sunitinib—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	3.72e-05	0.000265	CcSEcCtD
Sunitinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	3.71e-05	0.000264	CcSEcCtD
Sunitinib—Paraesthesia—Etoposide—peripheral nervous system neoplasm	3.67e-05	0.000262	CcSEcCtD
Sunitinib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	3.66e-05	0.000261	CcSEcCtD
Sunitinib—Weight decreased—Epirubicin—peripheral nervous system neoplasm	3.65e-05	0.00026	CcSEcCtD
Sunitinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	3.65e-05	0.00026	CcSEcCtD
Sunitinib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000259	CcSEcCtD
Sunitinib—Asthenia—Vincristine—peripheral nervous system neoplasm	3.62e-05	0.000258	CcSEcCtD
Sunitinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	3.62e-05	0.000258	CcSEcCtD
Sunitinib—PLK4—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.0111	CbGdCrCtD
Sunitinib—PLK4—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.6e-05	0.0111	CbGdCrCtD
Sunitinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000256	CcSEcCtD
Sunitinib—Infestation—Epirubicin—peripheral nervous system neoplasm	3.6e-05	0.000256	CcSEcCtD
Sunitinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	3.6e-05	0.000256	CcSEcCtD
Sunitinib—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000256	CcSEcCtD
Sunitinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	3.59e-05	0.000256	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	3.57e-05	0.000254	CcSEcCtD
Sunitinib—Rash—Dactinomycin—peripheral nervous system neoplasm	3.57e-05	0.000254	CcSEcCtD
Sunitinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	3.56e-05	0.000254	CcSEcCtD
Sunitinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000253	CcSEcCtD
Sunitinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	3.54e-05	0.000252	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	3.53e-05	0.000252	CcSEcCtD
Sunitinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	3.53e-05	0.000252	CcSEcCtD
Sunitinib—Fatigue—Etoposide—peripheral nervous system neoplasm	3.53e-05	0.000251	CcSEcCtD
Sunitinib—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	3.53e-05	0.000251	CcSEcCtD
Sunitinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.00025	CcSEcCtD
Sunitinib—Constipation—Etoposide—peripheral nervous system neoplasm	3.5e-05	0.000249	CcSEcCtD
Sunitinib—Pain—Etoposide—peripheral nervous system neoplasm	3.5e-05	0.000249	CcSEcCtD
Sunitinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	3.5e-05	0.000249	CcSEcCtD
Sunitinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000249	CcSEcCtD
Sunitinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000247	CcSEcCtD
Sunitinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	3.47e-05	0.000247	CcSEcCtD
Sunitinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	3.46e-05	0.000246	CcSEcCtD
Sunitinib—CHEK2—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	3.43e-05	0.0105	CbGdCrCtD
Sunitinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	3.4e-05	0.000242	CcSEcCtD
Sunitinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000242	CcSEcCtD
Sunitinib—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000241	CcSEcCtD
Sunitinib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.00024	CcSEcCtD
Sunitinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	3.36e-05	0.000239	CcSEcCtD
Sunitinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	3.35e-05	0.000239	CcSEcCtD
Sunitinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	3.35e-05	0.000238	CcSEcCtD
Sunitinib—Dizziness—Vincristine—peripheral nervous system neoplasm	3.34e-05	0.000238	CcSEcCtD
Sunitinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	3.33e-05	0.000238	CcSEcCtD
Sunitinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000237	CcSEcCtD
Sunitinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	3.33e-05	0.000237	CcSEcCtD
Sunitinib—Rash—Alitretinoin—peripheral nervous system neoplasm	3.31e-05	0.000236	CcSEcCtD
Sunitinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	3.3e-05	0.000235	CcSEcCtD
Sunitinib—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	3.3e-05	0.000235	CcSEcCtD
Sunitinib—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	3.29e-05	0.000235	CcSEcCtD
Sunitinib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	3.29e-05	0.000234	CcSEcCtD
Sunitinib—Headache—Alitretinoin—peripheral nervous system neoplasm	3.28e-05	0.000234	CcSEcCtD
Sunitinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	3.27e-05	0.000233	CcSEcCtD
Sunitinib—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	3.26e-05	0.000232	CcSEcCtD
Sunitinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	3.25e-05	0.000231	CcSEcCtD
Sunitinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000231	CcSEcCtD
Sunitinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	3.24e-05	0.000231	CcSEcCtD
Sunitinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	3.24e-05	0.000231	CcSEcCtD
Sunitinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	3.23e-05	0.000231	CcSEcCtD
Sunitinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.00023	CcSEcCtD
Sunitinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	3.23e-05	0.00023	CcSEcCtD
Sunitinib—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000229	CcSEcCtD
Sunitinib—Vomiting—Vincristine—peripheral nervous system neoplasm	3.21e-05	0.000229	CcSEcCtD
Sunitinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	3.2e-05	0.000228	CcSEcCtD
Sunitinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000227	CcSEcCtD
Sunitinib—Rash—Vincristine—peripheral nervous system neoplasm	3.19e-05	0.000227	CcSEcCtD
Sunitinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	3.18e-05	0.000227	CcSEcCtD
Sunitinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000227	CcSEcCtD
Sunitinib—CHEK2—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.17e-05	0.00976	CbGdCrCtD
Sunitinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000226	CcSEcCtD
Sunitinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	3.17e-05	0.000226	CcSEcCtD
Sunitinib—Headache—Vincristine—peripheral nervous system neoplasm	3.16e-05	0.000226	CcSEcCtD
Sunitinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	3.15e-05	0.000224	CcSEcCtD
Sunitinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000224	CcSEcCtD
Sunitinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	3.11e-05	0.000222	CcSEcCtD
Sunitinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	3.06e-05	0.000218	CcSEcCtD
Sunitinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	3.05e-05	0.000218	CcSEcCtD
Sunitinib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	3.04e-05	0.000217	CcSEcCtD
Sunitinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	3.02e-05	0.000215	CcSEcCtD
Sunitinib—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	3.02e-05	0.000215	CcSEcCtD
Sunitinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	3e-05	0.000214	CcSEcCtD
Sunitinib—Nausea—Vincristine—peripheral nervous system neoplasm	3e-05	0.000214	CcSEcCtD
Sunitinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000214	CcSEcCtD
Sunitinib—Flushing—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000214	CcSEcCtD
Sunitinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000213	CcSEcCtD
Sunitinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	2.99e-05	0.000213	CcSEcCtD
Sunitinib—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000212	CcSEcCtD
Sunitinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.00021	CcSEcCtD
Sunitinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.00021	CcSEcCtD
Sunitinib—Asthenia—Etoposide—peripheral nervous system neoplasm	2.94e-05	0.000209	CcSEcCtD
Sunitinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000209	CcSEcCtD
Sunitinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	2.93e-05	0.000209	CcSEcCtD
Sunitinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	2.93e-05	0.000209	CcSEcCtD
Sunitinib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	2.92e-05	0.000208	CcSEcCtD
Sunitinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000207	CcSEcCtD
Sunitinib—Chills—Epirubicin—peripheral nervous system neoplasm	2.9e-05	0.000206	CcSEcCtD
Sunitinib—Pruritus—Etoposide—peripheral nervous system neoplasm	2.9e-05	0.000206	CcSEcCtD
Sunitinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	2.88e-05	0.000206	CcSEcCtD
Sunitinib—Alopecia—Epirubicin—peripheral nervous system neoplasm	2.85e-05	0.000203	CcSEcCtD
Sunitinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	2.84e-05	0.000202	CcSEcCtD
Sunitinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	2.83e-05	0.000202	CcSEcCtD
Sunitinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	2.82e-05	0.000201	CcSEcCtD
Sunitinib—Rash—Cisplatin—peripheral nervous system neoplasm	2.82e-05	0.000201	CcSEcCtD
Sunitinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	2.81e-05	0.000201	CcSEcCtD
Sunitinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.0002	CcSEcCtD
Sunitinib—Erythema—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.0002	CcSEcCtD
Sunitinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	2.8e-05	0.0002	CcSEcCtD
Sunitinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000199	CcSEcCtD
Sunitinib—Flushing—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	0.000198	CcSEcCtD
Sunitinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	2.77e-05	0.000198	CcSEcCtD
Sunitinib—Flatulence—Epirubicin—peripheral nervous system neoplasm	2.77e-05	0.000197	CcSEcCtD
Sunitinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	2.75e-05	0.000196	CcSEcCtD
Sunitinib—Back pain—Epirubicin—peripheral nervous system neoplasm	2.72e-05	0.000194	CcSEcCtD
Sunitinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	2.71e-05	0.000193	CcSEcCtD
Sunitinib—Dizziness—Etoposide—peripheral nervous system neoplasm	2.71e-05	0.000193	CcSEcCtD
Sunitinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	2.7e-05	0.000193	CcSEcCtD
Sunitinib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	0.000192	CcSEcCtD
Sunitinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.69e-05	0.000192	CcSEcCtD
Sunitinib—Chills—Doxorubicin—peripheral nervous system neoplasm	2.68e-05	0.000191	CcSEcCtD
Sunitinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	2.67e-05	0.00019	CcSEcCtD
Sunitinib—Nausea—Cisplatin—peripheral nervous system neoplasm	2.65e-05	0.000189	CcSEcCtD
Sunitinib—Alopecia—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	0.000188	CcSEcCtD
Sunitinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	0.000187	CcSEcCtD
Sunitinib—Vomiting—Etoposide—peripheral nervous system neoplasm	2.6e-05	0.000185	CcSEcCtD
Sunitinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	0.000185	CcSEcCtD
Sunitinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	0.000185	CcSEcCtD
Sunitinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	2.6e-05	0.000185	CcSEcCtD
Sunitinib—Rash—Etoposide—peripheral nervous system neoplasm	2.58e-05	0.000184	CcSEcCtD
Sunitinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	2.58e-05	0.000184	CcSEcCtD
Sunitinib—Headache—Etoposide—peripheral nervous system neoplasm	2.56e-05	0.000183	CcSEcCtD
Sunitinib—Flatulence—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	0.000183	CcSEcCtD
Sunitinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	0.000181	CcSEcCtD
Sunitinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	2.52e-05	0.000179	CcSEcCtD
Sunitinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	2.52e-05	0.000179	CcSEcCtD
Sunitinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000178	CcSEcCtD
Sunitinib—Cough—Epirubicin—peripheral nervous system neoplasm	2.45e-05	0.000175	CcSEcCtD
Sunitinib—Convulsion—Epirubicin—peripheral nervous system neoplasm	2.44e-05	0.000174	CcSEcCtD
Sunitinib—Nausea—Etoposide—peripheral nervous system neoplasm	2.43e-05	0.000173	CcSEcCtD
Sunitinib—Hypertension—Epirubicin—peripheral nervous system neoplasm	2.43e-05	0.000173	CcSEcCtD
Sunitinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	0.000171	CcSEcCtD
Sunitinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	2.39e-05	0.000171	CcSEcCtD
Sunitinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	2.39e-05	0.000171	CcSEcCtD
Sunitinib—Chest pain—Epirubicin—peripheral nervous system neoplasm	2.39e-05	0.000171	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	2.38e-05	0.000169	CcSEcCtD
Sunitinib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	2.34e-05	0.000167	CcSEcCtD
Sunitinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	2.33e-05	0.000166	CcSEcCtD
Sunitinib—Oedema—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000163	CcSEcCtD
Sunitinib—Infection—Epirubicin—peripheral nervous system neoplasm	2.28e-05	0.000162	CcSEcCtD
Sunitinib—Cough—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	0.000162	CcSEcCtD
Sunitinib—Shock—Epirubicin—peripheral nervous system neoplasm	2.26e-05	0.000161	CcSEcCtD
Sunitinib—Convulsion—Doxorubicin—peripheral nervous system neoplasm	2.25e-05	0.000161	CcSEcCtD
Sunitinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	2.25e-05	0.00016	CcSEcCtD
Sunitinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.25e-05	0.00016	CcSEcCtD
Sunitinib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.25e-05	0.00016	CcSEcCtD
Sunitinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	2.23e-05	0.000159	CcSEcCtD
Sunitinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	0.000158	CcSEcCtD
Sunitinib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	0.000158	CcSEcCtD
Sunitinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	2.21e-05	0.000158	CcSEcCtD
Sunitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	2.2e-05	0.000157	CcSEcCtD
Sunitinib—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.19e-05	0.000156	CcSEcCtD
Sunitinib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.17e-05	0.000154	CcSEcCtD
Sunitinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	0.000151	CcSEcCtD
Sunitinib—Infection—Doxorubicin—peripheral nervous system neoplasm	2.11e-05	0.00015	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	2.09e-05	0.000149	CcSEcCtD
Sunitinib—Shock—Doxorubicin—peripheral nervous system neoplasm	2.09e-05	0.000149	CcSEcCtD
Sunitinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	2.08e-05	0.000148	CcSEcCtD
Sunitinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.08e-05	0.000148	CcSEcCtD
Sunitinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.07e-05	0.000148	CcSEcCtD
Sunitinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	2.06e-05	0.000147	CcSEcCtD
Sunitinib—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.06e-05	0.000147	CcSEcCtD
Sunitinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.05e-05	0.000146	CcSEcCtD
Sunitinib—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.02e-05	0.000144	CcSEcCtD
Sunitinib—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.02e-05	0.000144	CcSEcCtD
Sunitinib—ABCB1—cerebellum—peripheral nervous system neoplasm	2.02e-05	0.000305	CbGeAlD
Sunitinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	1.99e-05	0.000142	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	1.98e-05	0.000141	CcSEcCtD
Sunitinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	1.98e-05	0.000141	CcSEcCtD
Sunitinib—Pain—Epirubicin—peripheral nervous system neoplasm	1.96e-05	0.00014	CcSEcCtD
Sunitinib—Constipation—Epirubicin—peripheral nervous system neoplasm	1.96e-05	0.00014	CcSEcCtD
Sunitinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	1.93e-05	0.000138	CcSEcCtD
Sunitinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	1.92e-05	0.000137	CcSEcCtD
Sunitinib—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	1.91e-05	0.000136	CcSEcCtD
Sunitinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	1.89e-05	0.000135	CcSEcCtD
Sunitinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	1.88e-05	0.000134	CcSEcCtD
Sunitinib—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	1.87e-05	0.000133	CcSEcCtD
Sunitinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	1.85e-05	0.000131	CcSEcCtD
Sunitinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	1.83e-05	0.000131	CcSEcCtD
Sunitinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	1.83e-05	0.00013	CcSEcCtD
Sunitinib—Pain—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	0.000129	CcSEcCtD
Sunitinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	1.82e-05	0.000129	CcSEcCtD
Sunitinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.000129	CcSEcCtD
Sunitinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.000129	CcSEcCtD
Sunitinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	1.74e-05	0.000124	CcSEcCtD
Sunitinib—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.69e-05	0.00012	CcSEcCtD
Sunitinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.00012	CcSEcCtD
Sunitinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.00012	CcSEcCtD
Sunitinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.65e-05	0.000117	CcSEcCtD
Sunitinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.62e-05	0.000116	CcSEcCtD
Sunitinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.57e-05	0.000112	CcSEcCtD
Sunitinib—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.56e-05	0.000111	CcSEcCtD
Sunitinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.52e-05	0.000109	CcSEcCtD
Sunitinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.52e-05	0.000108	CcSEcCtD
Sunitinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.5e-05	0.000107	CcSEcCtD
Sunitinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.46e-05	0.000104	CcSEcCtD
Sunitinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.45e-05	0.000103	CcSEcCtD
Sunitinib—Rash—Epirubicin—peripheral nervous system neoplasm	1.45e-05	0.000103	CcSEcCtD
Sunitinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.45e-05	0.000103	CcSEcCtD
Sunitinib—Headache—Epirubicin—peripheral nervous system neoplasm	1.44e-05	0.000102	CcSEcCtD
Sunitinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.4e-05	0.0001	CcSEcCtD
Sunitinib—Nausea—Epirubicin—peripheral nervous system neoplasm	1.36e-05	9.71e-05	CcSEcCtD
Sunitinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.35e-05	9.62e-05	CcSEcCtD
Sunitinib—Rash—Doxorubicin—peripheral nervous system neoplasm	1.34e-05	9.54e-05	CcSEcCtD
Sunitinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.34e-05	9.53e-05	CcSEcCtD
Sunitinib—Headache—Doxorubicin—peripheral nervous system neoplasm	1.33e-05	9.48e-05	CcSEcCtD
Sunitinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.26e-05	8.98e-05	CcSEcCtD
Sunitinib—PDGFRB—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.3e-06	9.38e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.3e-06	9.38e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—NRAS—peripheral nervous system neoplasm	1.29e-06	9.32e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.29e-06	9.32e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.29e-06	9.3e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.27e-06	9.16e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—NRAS—peripheral nervous system neoplasm	1.27e-06	9.16e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.27e-06	9.14e-06	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—AKT1—peripheral nervous system neoplasm	1.27e-06	9.14e-06	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.26e-06	9.1e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.26e-06	9.09e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.26e-06	9.09e-06	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.25e-06	9.04e-06	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.25e-06	9.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.25e-06	9.01e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.25e-06	8.99e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.24e-06	8.95e-06	CbGpPWpGaD
Sunitinib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	1.24e-06	8.92e-06	CbGpPWpGaD
Sunitinib—FGR—Immune System—AKT1—peripheral nervous system neoplasm	1.23e-06	8.89e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.23e-06	8.87e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.22e-06	8.81e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—MYC—peripheral nervous system neoplasm	1.22e-06	8.79e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.22e-06	8.77e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.21e-06	8.75e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.21e-06	8.72e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	1.21e-06	8.72e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—NRAS—peripheral nervous system neoplasm	1.21e-06	8.69e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.21e-06	8.69e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—MYC—peripheral nervous system neoplasm	1.2e-06	8.68e-06	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.2e-06	8.68e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—NRAS—peripheral nervous system neoplasm	1.2e-06	8.67e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—NRAS—peripheral nervous system neoplasm	1.2e-06	8.67e-06	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.19e-06	8.59e-06	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.19e-06	8.58e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.19e-06	8.58e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.19e-06	8.57e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.19e-06	8.57e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	1.19e-06	8.55e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—MYC—peripheral nervous system neoplasm	1.18e-06	8.53e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.18e-06	8.52e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.18e-06	8.48e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.18e-06	8.48e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.18e-06	8.48e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	1.17e-06	8.46e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.17e-06	8.43e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.17e-06	8.43e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.16e-06	8.33e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.15e-06	8.27e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.14e-06	8.21e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.14e-06	8.2e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.14e-06	8.19e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.13e-06	8.18e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—NRAS—peripheral nervous system neoplasm	1.13e-06	8.15e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.13e-06	8.15e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.13e-06	8.12e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—HRAS—peripheral nervous system neoplasm	1.13e-06	8.12e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—NRAS—peripheral nervous system neoplasm	1.12e-06	8.11e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—MYC—peripheral nervous system neoplasm	1.12e-06	8.09e-06	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.12e-06	8.09e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—MYC—peripheral nervous system neoplasm	1.12e-06	8.07e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.12e-06	8.06e-06	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.11e-06	8.03e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—NRAS—peripheral nervous system neoplasm	1.11e-06	8e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.11e-06	8e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.11e-06	7.98e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.1e-06	7.9e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.1e-06	7.9e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.09e-06	7.89e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.09e-06	7.85e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	1.08e-06	7.81e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.08e-06	7.79e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—NRAS—peripheral nervous system neoplasm	1.07e-06	7.75e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—HRAS—peripheral nervous system neoplasm	1.07e-06	7.7e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.07e-06	7.7e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.07e-06	7.7e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.06e-06	7.65e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.06e-06	7.65e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.06e-06	7.63e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—NRAS—peripheral nervous system neoplasm	1.04e-06	7.53e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—NRAS—peripheral nervous system neoplasm	1.04e-06	7.49e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—HRAS—peripheral nervous system neoplasm	1.04e-06	7.48e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—MYC—peripheral nervous system neoplasm	1.03e-06	7.45e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—HRAS—peripheral nervous system neoplasm	1.02e-06	7.39e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.02e-06	7.37e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.02e-06	7.36e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.01e-06	7.3e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	1.01e-06	7.27e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.01e-06	7.26e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—HRAS—peripheral nervous system neoplasm	1.01e-06	7.25e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—HRAS—peripheral nervous system neoplasm	1.01e-06	7.25e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1e-06	7.24e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1e-06	7.23e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.97e-07	7.19e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.96e-07	7.18e-06	CbGpPWpGaD
Sunitinib—YES1—Immune System—AKT1—peripheral nervous system neoplasm	9.95e-07	7.17e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—NRAS—peripheral nervous system neoplasm	9.92e-07	7.15e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—MYC—peripheral nervous system neoplasm	9.72e-07	7.01e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.7e-07	6.99e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—MYC—peripheral nervous system neoplasm	9.67e-07	6.97e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9.62e-07	6.94e-06	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.62e-07	6.93e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.61e-07	6.93e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—HRAS—peripheral nervous system neoplasm	9.58e-07	6.91e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.56e-07	6.89e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—HRAS—peripheral nervous system neoplasm	9.55e-07	6.89e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—HRAS—peripheral nervous system neoplasm	9.53e-07	6.87e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—HRAS—peripheral nervous system neoplasm	9.46e-07	6.82e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.44e-07	6.81e-06	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—AKT1—peripheral nervous system neoplasm	9.44e-07	6.8e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.34e-07	6.74e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—HRAS—peripheral nervous system neoplasm	9.29e-07	6.7e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.28e-07	6.69e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.28e-07	6.69e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.28e-07	6.69e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.27e-07	6.68e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—MYC—peripheral nervous system neoplasm	9.24e-07	6.66e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.17e-07	6.61e-06	CbGpPWpGaD
Sunitinib—TYK2—Immune System—AKT1—peripheral nervous system neoplasm	9.16e-07	6.6e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	9.13e-07	6.58e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	9.12e-07	6.58e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.05e-07	6.53e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.05e-07	6.52e-06	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—AKT1—peripheral nervous system neoplasm	9.05e-07	6.52e-06	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.02e-07	6.5e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9e-07	6.49e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	9e-07	6.49e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	9e-07	6.49e-06	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.94e-07	6.45e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.94e-07	6.44e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.89e-07	6.41e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.89e-07	6.41e-06	CbGpPWpGaD
Sunitinib—KIT—Immune System—AKT1—peripheral nervous system neoplasm	8.88e-07	6.41e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—AKT1—peripheral nervous system neoplasm	8.88e-07	6.41e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.88e-07	6.4e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—HRAS—peripheral nervous system neoplasm	8.82e-07	6.36e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.8e-07	6.34e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—HRAS—peripheral nervous system neoplasm	8.79e-07	6.34e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—HRAS—peripheral nervous system neoplasm	8.79e-07	6.34e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.77e-07	6.33e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.72e-07	6.29e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.67e-07	6.25e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	8.67e-07	6.25e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.61e-07	6.21e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.61e-07	6.21e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	8.61e-07	6.2e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	8.58e-07	6.19e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.54e-07	6.16e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	8.5e-07	6.13e-06	CbGpPWpGaD
Sunitinib—TYK2—Disease—AKT1—peripheral nervous system neoplasm	8.46e-07	6.1e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.44e-07	6.08e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.43e-07	6.08e-06	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—AKT1—peripheral nervous system neoplasm	8.43e-07	6.08e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.42e-07	6.07e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—AKT1—peripheral nervous system neoplasm	8.41e-07	6.06e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.39e-07	6.05e-06	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	8.37e-07	6.03e-06	CbGpPWpGaD
Sunitinib—FGFR2—Disease—AKT1—peripheral nervous system neoplasm	8.35e-07	6.02e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8.29e-07	5.98e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.28e-07	5.97e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.28e-07	5.97e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—HRAS—peripheral nervous system neoplasm	8.27e-07	5.96e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—HRAS—peripheral nervous system neoplasm	8.23e-07	5.93e-06	CbGpPWpGaD
Sunitinib—KIT—Disease—AKT1—peripheral nervous system neoplasm	8.2e-07	5.91e-06	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.19e-07	5.91e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—HRAS—peripheral nervous system neoplasm	8.12e-07	5.85e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.95e-07	5.73e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	7.92e-07	5.71e-06	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.89e-07	5.69e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—HRAS—peripheral nervous system neoplasm	7.86e-07	5.67e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.86e-07	5.67e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.84e-07	5.65e-06	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.84e-07	5.65e-06	CbGpPWpGaD
Sunitinib—FGFR1—Disease—AKT1—peripheral nervous system neoplasm	7.79e-07	5.61e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.77e-07	5.6e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—AKT1—peripheral nervous system neoplasm	7.77e-07	5.6e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—AKT1—peripheral nervous system neoplasm	7.76e-07	5.6e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—HRAS—peripheral nervous system neoplasm	7.64e-07	5.51e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.62e-07	5.49e-06	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.6e-07	5.48e-06	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.6e-07	5.48e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.6e-07	5.48e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—HRAS—peripheral nervous system neoplasm	7.6e-07	5.48e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.58e-07	5.47e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	7.58e-07	5.46e-06	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.41e-07	5.34e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	7.32e-07	5.28e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.31e-07	5.27e-06	CbGpPWpGaD
Sunitinib—FYN—Immune System—AKT1—peripheral nervous system neoplasm	7.3e-07	5.27e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.28e-07	5.25e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.27e-07	5.24e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—AKT1—peripheral nervous system neoplasm	7.26e-07	5.24e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—HRAS—peripheral nervous system neoplasm	7.26e-07	5.23e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.24e-07	5.22e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.22e-07	5.21e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—AKT1—peripheral nervous system neoplasm	7.17e-07	5.17e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.06e-07	5.09e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.01e-07	5.06e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	7e-07	5.04e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.99e-07	5.04e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.95e-07	5.01e-06	CbGpPWpGaD
Sunitinib—JAK2—Immune System—AKT1—peripheral nervous system neoplasm	6.94e-07	5.01e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.93e-07	4.99e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.91e-07	4.98e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	6.89e-07	4.96e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.81e-07	4.91e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.8e-07	4.9e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.8e-07	4.9e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.77e-07	4.88e-06	CbGpPWpGaD
Sunitinib—FYN—Disease—AKT1—peripheral nervous system neoplasm	6.74e-07	4.86e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.71e-07	4.84e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—AKT1—peripheral nervous system neoplasm	6.71e-07	4.84e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.62e-07	4.78e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.51e-07	4.69e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.51e-07	4.69e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.47e-07	4.67e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.46e-07	4.65e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.44e-07	4.64e-06	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.43e-07	4.64e-06	CbGpPWpGaD
Sunitinib—JAK2—Disease—AKT1—peripheral nervous system neoplasm	6.41e-07	4.62e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.17e-07	4.45e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.16e-07	4.44e-06	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.1e-07	4.4e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.94e-07	4.29e-06	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.92e-07	4.27e-06	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.85e-07	4.22e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.8e-07	4.18e-06	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.74e-07	4.14e-06	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.74e-07	4.14e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.69e-07	4.1e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	5.62e-07	4.05e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.59e-07	4.03e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.56e-07	4.01e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.55e-07	4e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	5.52e-07	3.98e-06	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.45e-07	3.93e-06	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.44e-07	3.92e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.35e-07	3.86e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.32e-07	3.83e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.32e-07	3.83e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.08e-07	3.66e-06	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.02e-07	3.62e-06	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.9e-07	3.53e-06	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.72e-07	3.4e-06	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.7e-07	3.39e-06	CbGpPWpGaD
Sunitinib—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	4.55e-07	3.28e-06	CbGpPWpGaD
Sunitinib—CYP3A7—Metabolism—AKT1—peripheral nervous system neoplasm	4.51e-07	3.25e-06	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.49e-07	3.24e-06	CbGpPWpGaD
Sunitinib—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	3.26e-07	2.35e-06	CbGpPWpGaD
Sunitinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.46e-07	1.78e-06	CbGpPWpGaD
Sunitinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.52e-07	1.09e-06	CbGpPWpGaD
